Log in

NYSE:BHC - Bausch Health Companies Stock Price, Forecast & News

$31.89
+2.56 (+8.73 %)
(As of 12/13/2019 03:42 AM ET)
Today's Range
$29.66
Now: $31.89
$31.97
50-Day Range
$22.53
MA: $27.10
$31.85
52-Week Range
$17.20
Now: $31.89
$31.97
Volume13.21 million shs
Average Volume3.87 million shs
Market Capitalization$11.24 billion
P/E Ratio7.93
Dividend YieldN/A
Beta0.9
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone514-744-6792

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8.38 billion
Cash Flow$13.46 per share
Book Value$8.05 per share

Profitability

Net Income$-4,148,000,000.00

Miscellaneous

Employees21,100
Market Cap$11.24 billion
Next Earnings Date2/19/2020 (Estimated)
OptionableOptionable

Receive BHC News and Ratings via Email

Sign-up to receive the latest news and ratings for BHC and its competitors with MarketBeat's FREE daily newsletter.


Bausch Health Companies (NYSE:BHC) Frequently Asked Questions

What is Bausch Health Companies' stock symbol?

Bausch Health Companies trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHC."

How were Bausch Health Companies' earnings last quarter?

Bausch Health Companies Inc (NYSE:BHC) posted its quarterly earnings results on Monday, November, 4th. The company reported $1.19 EPS for the quarter, topping the Zacks' consensus estimate of $1.06 by $0.13. The company had revenue of $2.21 billion for the quarter, compared to analysts' expectations of $2.15 billion. Bausch Health Companies had a positive return on equity of 56.19% and a negative net margin of 7.25%. View Bausch Health Companies' Earnings History.

When is Bausch Health Companies' next earnings date?

Bausch Health Companies is scheduled to release their next quarterly earnings announcement on Wednesday, February 19th 2020. View Earnings Estimates for Bausch Health Companies.

What price target have analysts set for BHC?

16 brokerages have issued 1 year target prices for Bausch Health Companies' shares. Their forecasts range from $9.00 to $60.00. On average, they anticipate Bausch Health Companies' stock price to reach $31.80 in the next twelve months. This suggests that the stock has a possible downside of 0.3%. View Analyst Price Targets for Bausch Health Companies.

What is the consensus analysts' recommendation for Bausch Health Companies?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bausch Health Companies in the last year. There are currently 2 sell ratings, 1 hold rating and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bausch Health Companies.

What are Wall Street analysts saying about Bausch Health Companies stock?

Here are some recent quotes from research analysts about Bausch Health Companies stock:
  • 1. According to Zacks Investment Research, "Bausch beat both earnings and sales estimates in the third quarter and raised annual guidance. Both the Bausch + Lomb/International and Salix segments drove the quarterly performance on higher revenues in several established brands, such as Xifaxan, BioTrue ONEday and Bausch + Lomb ULTRA. Newer products, such as Lumify and Thermage FLX, also performed well. The initial uptake of psoriasis lotion, Duobrii, has been encouraging as well. After a tumultuous period, the company started a rebuilding process. Bausch has narrowed its focus on seven products — Vyzulta, Siliq, Bryhali, Lumify, Duobrii, Relistor and SiHy Daily. These have now been launched and hence the company’s performance is expected to be strong. However, the dermatology market continues to be challenging. Shares have outperformed the industry in the year so far." (11/6/2019)
  • 2. HC Wainwright analysts commented, "Valuation methodology, risks, and uncertainties. We employ a cash EPS multiple-based approach. The cash EPS number is derived from our adjusted 12-month income, which employs a total 12-month adjusted (non-GAAP) income projection of roughly $1.6B, which we divide by approximately 357M shares outstanding to derive our 12-month cash EPS of $4.46 per share." (8/7/2019)
  • 3. Cantor Fitzgerald analysts commented, "We rate BHC as 12-month price target of $32. A greater appreciation for BHC’s solid execution and future growth prospects under the new management team should drive upwards earnings revisions in 2019+, multiple expansion, and BHC shares higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $32." (4/25/2019)

Has Bausch Health Companies been receiving favorable news coverage?

Press coverage about BHC stock has been trending neutral on Friday, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Bausch Health Companies earned a coverage optimism score of 0.4 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Bausch Health Companies.

Are investors shorting Bausch Health Companies?

Bausch Health Companies saw a increase in short interest in the month of November. As of November 29th, there was short interest totalling 12,190,000 shares, an increase of 13.5% from the November 14th total of 10,740,000 shares. Based on an average trading volume of 3,950,000 shares, the short-interest ratio is currently 3.1 days. Currently, 3.5% of the shares of the stock are short sold. View Bausch Health Companies' Current Options Chain.

Who are some of Bausch Health Companies' key competitors?

What other stocks do shareholders of Bausch Health Companies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bausch Health Companies investors own include Constellation Software (CSU), Intact Financial (IFC), Gilead Sciences (GILD), Micron Technology (MU), Twitter (TWTR), Netflix (NFLX), Alibaba Group (BABA), Bank of America (BAC), NVIDIA (NVDA) and Tesla (TSLA).

Who are Bausch Health Companies' key executives?

Bausch Health Companies' management team includes the folowing people:
  • Mr. Joseph C. Papa, CEO & Chairman (Age 64)
  • Mr. Paul S. Herendeen, Exec. VP & CFO (Age 63)
  • Mr. Thomas J. Appio, Pres & Co-Head Bausch + Lomb/International (Age 57)
  • Mr. William D. Humphries, Pres of Ortho-Dermatologics (Age 53)
  • Mr. Osama A. Eldessouky, Sr. VP, Controller & Chief Accounting Officer (Age 47)

Who are Bausch Health Companies' major shareholders?

Bausch Health Companies' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Orbimed Advisors LLC (0.94%), Point72 Asset Management L.P. (0.62%), Ardevora Asset Management LLP (0.54%), Alberta Investment Management Corp (0.39%), Commerzbank Aktiengesellschaft FI (0.30%) and Sumitomo Mitsui Trust Holdings Inc. (0.21%). Company insiders that own Bausch Health Companies stock include Christina Ackermann, John Paulson, Joseph C Papa, Mark C Mckenna, Paul Herendeen, Schutter Richard U De, Thomas Appio and William D Humphries. View Institutional Ownership Trends for Bausch Health Companies.

Which institutional investors are selling Bausch Health Companies stock?

BHC stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Man Group plc, Parametric Portfolio Associates LLC, Point72 Asset Management L.P., Zurcher Kantonalbank Zurich Cantonalbank, Stifel Financial Corp, Maverick Capital Ltd. and Daiwa Securities Group Inc.. Company insiders that have sold Bausch Health Companies company stock in the last year include Christina Ackermann and Mark C Mckenna. View Insider Buying and Selling for Bausch Health Companies.

Which institutional investors are buying Bausch Health Companies stock?

BHC stock was bought by a variety of institutional investors in the last quarter, including Commerzbank Aktiengesellschaft FI, Millennium Management LLC, Academy Capital Management Inc. TX, Ardevora Asset Management LLP, Gabelli Funds LLC, Squarepoint Ops LLC, Alberta Investment Management Corp and Nisa Investment Advisors LLC. Company insiders that have bought Bausch Health Companies stock in the last two years include John Paulson, Joseph C Papa, Paul Herendeen, Schutter Richard U De, Thomas Appio and William D Humphries. View Insider Buying and Selling for Bausch Health Companies.

How do I buy shares of Bausch Health Companies?

Shares of BHC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Bausch Health Companies' stock price today?

One share of BHC stock can currently be purchased for approximately $31.89.

How big of a company is Bausch Health Companies?

Bausch Health Companies has a market capitalization of $11.24 billion and generates $8.38 billion in revenue each year. The company earns $-4,148,000,000.00 in net income (profit) each year or $4.02 on an earnings per share basis. Bausch Health Companies employs 21,100 workers across the globe.View Additional Information About Bausch Health Companies.

What is Bausch Health Companies' official website?

The official website for Bausch Health Companies is http://www.bauschhealth.com/.

How can I contact Bausch Health Companies?

Bausch Health Companies' mailing address is 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8. The company can be reached via phone at 514-744-6792 or via email at [email protected]


MarketBeat Community Rating for Bausch Health Companies (NYSE BHC)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  269 (Vote Outperform)
Underperform Votes:  295 (Vote Underperform)
Total Votes:  564
MarketBeat's community ratings are surveys of what our community members think about Bausch Health Companies and other stocks. Vote "Outperform" if you believe BHC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BHC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel